Publications by authors named "Rachel Grocott"

Claim this Profile
C
Comment on "ahead of its time? Reflecting on New Zealand's Pharmac following its 20th anniversary" : clarification from PHARMAC: PHARMAC takes no particular distributive approach (utilitarian or otherwise).
Scott Metcalfe, Rachel Grocott, Dilky Rasiah

Pharmacoeconomics· October 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Assessing the value for money of pharmaceuticals in New Zealand--PHARMAC's approach to cost-utility analysis.
Rachel Grocott, Scott Metcalfe, Paul Alexander, Rachel Werner

N Z Med J· July 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
PHARMAC's updated guidelines for cost-utility analyses, with new QALYs per $1M metric.
Rachel Grocott, Scott Metcalfe

N Z Med J· July 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comments on "Simoens, S. Health economic assessment: a methodological primer. Int. J. Environ. Res. Public Health 2009, 6, 2950-2966"-New Zealand in fact has no cost-effectiveness threshold.
Scott Metcalfe, Rachel Grocott

Int J Environ Res Public Health· April 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Applying Programme Budgeting Marginal Analysis in the health sector: 12 years of experience.
Rachel Grocott

Expert Rev Pharmacoecon Outcomes Res· April 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
PHARMAC's updated guidelines for cost-effectiveness analyses, with new discount rate.
Rachel Grocott, Scott Metcalfe

N Z Med J· July 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
PHARMAC seeks clinical feedback on its cost-utility analysis methodology.
Rachel Grocott, Peter Moodie

N Z Med J· August 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
PHARMAC and erythropoietin for cancer patients.
Rachel Grocott, Scott Metcalfe, Peter Moodie

N Z Med J· June 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
PHARMAC responds on TNF inhibitors for inflammatory arthritis.
Scott Metcalfe, Peter Moodie, Rachel Grocott, Tommy Wilkinson

N Z Med J· December 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Going against the flow: the impact of PHARMAC not funding COX-2 inhibitors for chronic arthritis.
Rachel Grocott, Scott Metcalfe

N Z Med J· October 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
PHARMAC responds to Richard Milne on discounting health benefits and costs.
Scott Metcalfe, Matthew Brougham, Peter Moodie, Rachel Grocott

N Z Med J· July 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis